Do analysts rate PALI or ICCC?

Palisade Bio currently has a consensus price target of $9.00, suggesting a potential upside of 336.89%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Palisade Bio is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, PALI or ICCC?

ImmuCell has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palisade Bio $250K 1,435.98 -$16.78M -$0.48 N/A ImmuCell $27.64M 3.24 -$1.04M $0.08 123.13

Is PALI or ICCC more profitable?

ImmuCell has a net margin of 2.57% compared to Palisade Bio's net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% ImmuCell 2.57% 2.69% 1.76%

Does the media refer more to PALI or ICCC?

In the previous week, Palisade Bio had 1 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Palisade Bio and 2 mentions for ImmuCell. Palisade Bio's average media sentiment score of 1.63 beat ImmuCell's score of 1.52 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ImmuCell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate ICCC or IKT?

Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 130.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Inhibikase Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.00

Does the media favor VNDA or ICCC?

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 2 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat ImmuCell's score of 1.52 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ImmuCell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend ICCC or AMRN?

Amarin has a consensus target price of $13.00, indicating a potential downside of 5.80%. Given Amarin's higher possible upside, analysts clearly believe Amarin is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33

Which has better valuation & earnings, ICCC or AMRN?

ImmuCell has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.24 -$1.04M $0.08 123.13 Amarin $213.65M 1.36 -$38.80M -$0.99 N/A

Is ICCC or AMRN more profitable?

ImmuCell has a net margin of 2.57% compared to Amarin's net margin of -14.56%. ImmuCell's return on equity of 2.69% beat Amarin's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell 2.57% 2.69% 1.76% Amarin -14.56% -0.20% -0.14%

Does the media prefer ICCC or AMRN?

In the previous week, ImmuCell and ImmuCell both had 2 articles in the media. ImmuCell's average media sentiment score of 1.52 beat Amarin's score of 0.54 indicating that ImmuCell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ICCC or ZNTL?

Zentalis Pharmaceuticals has a consensus price target of $6.75, indicating a potential upside of 92.31%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Zentalis Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to ICCC or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 2 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.52 beat Zentalis Pharmaceuticals' score of 1.07 indicating that ImmuCell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ImmuCell (ICCC) Competitors

$9.85 -0.06 (-0.61%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$9.87 +0.02 (+0.20%)

As of 09/11/2026 07:30 PM Eastern

Compare

ICCC vs. PALI, IKT, VNDA, AMRN, and ZNTL

Should you buy ImmuCell stock or one of its competitors? ImmuCell's main competitors and comparable companies include Palisade Bio (PALI), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), and Zentalis Pharmaceuticals (ZNTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ImmuCell compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Palisade Bio currently has a consensus price target of $9.00, suggesting a potential upside of 336.89%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Palisade Bio is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

ImmuCell has a net margin of 2.57% compared to Palisade Bio's net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
ImmuCell	2.57%	2.69%	1.76%

Palisade Bio has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

In the previous week, Palisade Bio had 1 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Palisade Bio and 2 mentions for ImmuCell. Palisade Bio's average media sentiment score of 1.63 beat ImmuCell's score of 1.52 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ImmuCell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 5.7% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ImmuCell has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,435.98	-$16.78M	-$0.48	N/A
ImmuCell	$27.64M	3.24	-$1.04M	$0.08	123.13

Summary

ImmuCell beats Palisade Bio on 9 of the 17 factors compared between the two stocks.

How does ImmuCell compare to Inhibikase Therapeutics?

ImmuCell (NASDAQ:ICCC) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

ImmuCell has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.24	-$1.04M	$0.08	123.13
Inhibikase Therapeutics	$260K	1,255.86	-$48.26M	-$0.43	N/A

ImmuCell has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ImmuCell has a net margin of 2.57% compared to Inhibikase Therapeutics' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 130.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, ImmuCell had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 2 mentions for ImmuCell and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.89 beat ImmuCell's score of 1.52 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmuCell	Very Positive
Inhibikase Therapeutics	Very Positive

Summary

ImmuCell and Inhibikase Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vanda Pharmaceuticals currently has a consensus price target of $13.70, indicating a potential upside of 169.16%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vanda Pharmaceuticals is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

ImmuCell has a net margin of 2.57% compared to Vanda Pharmaceuticals' net margin of -127.41%. ImmuCell's return on equity of 2.69% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
ImmuCell	2.57%	2.69%	1.76%

Vanda Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 2 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat ImmuCell's score of 1.52 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ImmuCell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ImmuCell has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.63	N/A
ImmuCell	$27.64M	3.24	-$1.04M	$0.08	123.13

Summary

Vanda Pharmaceuticals beats ImmuCell on 8 of the 15 factors compared between the two stocks.

How does ImmuCell compare to Amarin?

ImmuCell (NASDAQ:ICCC) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

ImmuCell has a net margin of 2.57% compared to Amarin's net margin of -14.56%. ImmuCell's return on equity of 2.69% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Amarin	-14.56%	-0.20%	-0.14%

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, ImmuCell and ImmuCell both had 2 articles in the media. ImmuCell's average media sentiment score of 1.52 beat Amarin's score of 0.54 indicating that ImmuCell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuCell has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Amarin has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Amarin has a consensus target price of $13.00, indicating a potential downside of 5.80%. Given Amarin's higher possible upside, analysts clearly believe Amarin is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

ImmuCell has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.24	-$1.04M	$0.08	123.13
Amarin	$213.65M	1.36	-$38.80M	-$0.99	N/A

Summary

ImmuCell beats Amarin on 10 of the 14 factors compared between the two stocks.

How does ImmuCell compare to Zentalis Pharmaceuticals?

ImmuCell (NASDAQ:ICCC) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

ImmuCell has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.24	-$1.04M	$0.08	123.13
Zentalis Pharmaceuticals	$67.43M	3.73	-$137.06M	-$1.95	N/A

13.5% of ImmuCell shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ImmuCell has a net margin of 2.57% compared to Zentalis Pharmaceuticals' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

ImmuCell has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market.

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 2 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.52 beat Zentalis Pharmaceuticals' score of 1.07 indicating that ImmuCell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zentalis Pharmaceuticals has a consensus price target of $6.75, indicating a potential upside of 92.31%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

ImmuCell beats Zentalis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get ImmuCell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCC vs. The Competition

Export

Metric	ImmuCell	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$89.46M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	123.14	656.81	214.39	20.85
Price / Sales	3.24	756.96	633.80	90.72
Price / Cash	51.09	14.86	28.42	34.96
Price / Book	3.29	10.39	10.33	6.21
Net Income	-$1.04M	$2.85B	$3.50B	$358.54M
7 Day Performance	-0.51%	-3.61%	-3.32%	-2.35%
1 Month Performance	-9.63%	0.72%	-0.53%	-3.23%
1 Year Performance	66.39%	3.61%	23.51%	8.79%

ImmuCell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCC ImmuCell	1.4997 of 5 stars	$9.85 -0.6%	N/A	+66.4%	$89.46M	$27.64M	123.14	70
PALI Palisade Bio	3.1216 of 5 stars	$2.05 -6.8%	$9.00 +339.0%	+244.5%	$357.26M	$500K	N/A	10	Positive News
IKT Inhibikase Therapeutics	2.2959 of 5 stars	$2.41 -0.8%	$5.40 +124.1%	+50.0%	$336.28M	N/A	N/A	6
VNDA Vanda Pharmaceuticals	3.0217 of 5 stars	$5.25 -1.5%	$13.70 +161.0%	+12.9%	$317.43M	$215.72M	N/A	290
AMRN Amarin	0.9442 of 5 stars	$14.39 +1.0%	$13.00 -9.7%	-8.1%	$303.96M	$186.23M	N/A	360

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCC) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuCell (ICCC) Competitors

ICCC vs. PALI, IKT, VNDA, AMRN, and ZNTL

How does ImmuCell compare to Palisade Bio?

Summary

How does ImmuCell compare to Inhibikase Therapeutics?

Summary

How does ImmuCell compare to Vanda Pharmaceuticals?

Summary

How does ImmuCell compare to Amarin?

Summary

How does ImmuCell compare to Zentalis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuCell (ICCC) Competitors

ICCC vs. PALI, IKT, VNDA, AMRN, and ZNTL

How does ImmuCell compare to Palisade Bio?

Do analysts rate PALI or ICCC?

Is PALI or ICCC more profitable?

Which has more risk and volatility, PALI or ICCC?

Does the media refer more to PALI or ICCC?

Do institutionals & insiders hold more shares of PALI or ICCC?

Which has preferable valuation & earnings, PALI or ICCC?

Summary

How does ImmuCell compare to Inhibikase Therapeutics?

Which has higher earnings & valuation, ICCC or IKT?

Which has more volatility & risk, ICCC or IKT?

Do insiders and institutionals hold more shares of ICCC or IKT?

Is ICCC or IKT more profitable?

Do analysts rate ICCC or IKT?

Does the media refer more to ICCC or IKT?

Summary

How does ImmuCell compare to Vanda Pharmaceuticals?

Do insiders & institutionals have more ownership in VNDA or ICCC?

Do analysts rate VNDA or ICCC?

Is VNDA or ICCC more profitable?

Which has more volatility and risk, VNDA or ICCC?

Does the media favor VNDA or ICCC?

Which has better earnings & valuation, VNDA or ICCC?

Summary

How does ImmuCell compare to Amarin?

Is ICCC or AMRN more profitable?

Do insiders and institutionals have more ownership in ICCC or AMRN?

Does the media prefer ICCC or AMRN?

Which has more risk & volatility, ICCC or AMRN?

Do analysts recommend ICCC or AMRN?

Which has better valuation & earnings, ICCC or AMRN?

Summary

How does ImmuCell compare to Zentalis Pharmaceuticals?

Which has better valuation and earnings, ICCC or ZNTL?

Do insiders & institutionals believe in ICCC or ZNTL?

Is ICCC or ZNTL more profitable?

Which has more risk & volatility, ICCC or ZNTL?

Does the media refer more to ICCC or ZNTL?

Do analysts prefer ICCC or ZNTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools